A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

October 20, 2026

Study Completion Date

October 20, 2026

Conditions

Relapse/Refractory Multiple Myeloma

Interventions

BIOLOGICAL

DeepTag-GPRC5D Targeted CAR T-cells

Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion

Trial Locations (1)

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors

collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

He Huang

OTHER